Home » Topics » Cancer, BioWorld Science

Cancer, BioWorld Science
RSS

FDA accepts Enzon's IND to initiate phase I study of its survivin antagonist

Feb. 11, 2009

Cell and IDIS sign collaborative agreement for pixantrone named-patient program

Feb. 11, 2009

Viralytics initiates head and neck cancer trial with Cavatak

Feb. 11, 2009

New PARP-1 inhibitors with anticancer activity discovered at AstraZeneca

Feb. 11, 2009

Critical Outcome Technologies reports results from in vitro studies of oncology drug COTI-2

Feb. 10, 2009

MCT1 inhibition blocks hypoxic-oxygenated tumor cell symbiosis and leads to cell death

Feb. 10, 2009

EntreMed presents initial preclinical and phase I results for ENMD-2076

Feb. 10, 2009

Genentech collaborates with National Cancer Institute on GDC-0449

Feb. 10, 2009

New PI3K inhibitors imparted in recent UCB patent

Feb. 10, 2009

Tigris files IND for anticancer drug GGTI-2418

Feb. 9, 2009

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Skape Bio unlocks GPCR targets with de novo-designed miniproteins
BioWorld
Modulating G protein-coupled receptors (GPCRs) is one of the major challenges in biomedicine. These are flexible proteins with small, deep binding pockets. The...
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
New 5-HT2C receptor agonists reported in Hansoh patent
BioWorld Science
Researchers from Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have disclosed tricyclic compounds acting as 5-HT2C receptor...